[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:transient-ischemic-attack":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":93,"states":94},"Transient Ischemic Attack",13,9,[8,15,21,27,33,39,45,51,57,63,71,79,86],{"nct_id":9,"title":10,"phases":11,"status":12,"updated_at":13,"content_modified":14},"NCT02098265","A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device",[],"RECRUITING","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:28.477267Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06605014","Somatic Dysfunction in Patients With Acute Cerebrovascular Disease",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.555230Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06292117","Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke",[],"2026-08-26T02:19:04.543908Z","2026-05-13T02:55:06.432625Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":31,"content_modified":32},"NCT05518305","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis",[],"2026-08-26T02:16:12.203827Z","2026-05-13T02:55:06.352763Z",{"nct_id":34,"title":35,"phases":36,"status":12,"updated_at":37,"content_modified":38},"NCT00009243","Natural History of Stroke: Cause and Development",[],"2026-08-26T02:17:49.709549Z","2026-05-13T02:55:06.027336Z",{"nct_id":40,"title":41,"phases":42,"status":12,"updated_at":43,"content_modified":44},"NCT06753045","Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.569449Z",{"nct_id":46,"title":47,"phases":48,"status":12,"updated_at":49,"content_modified":50},"NCT02693223","Get With the Guidelines-Stroke Registry",[],"2026-08-26T02:15:03.757872Z","2026-05-13T02:55:06.099212Z",{"nct_id":52,"title":53,"phases":54,"status":12,"updated_at":55,"content_modified":56},"NCT06943586","Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing",[],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:29.361227Z",{"nct_id":58,"title":59,"phases":60,"status":12,"updated_at":61,"content_modified":62},"NCT06368193","The Neuralert Stroke Monitor Pilot Trial",[],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:28.733029Z",{"nct_id":64,"title":65,"phases":66,"status":68,"updated_at":69,"content_modified":70},"NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial",[67],"Phase 3","NOT_YET_RECRUITING","2026-08-26T02:16:29.226604Z","2026-05-05T02:43:29.729314Z",{"nct_id":72,"title":73,"phases":74,"status":76,"updated_at":77,"content_modified":78},"NCT06040255","Focal Cerebral Arteriopathy Steroid Trial",[75],"Phase 4","ENROLLING_BY_INVITATION","2026-08-26T02:18:18.766496Z","2026-06-16T05:54:08.098421Z",{"nct_id":80,"title":81,"phases":82,"status":83,"updated_at":84,"content_modified":85},"NCT05702034","A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE",[67],"ACTIVE_NOT_RECRUITING","2026-08-03T02:09:46.172607Z","2026-05-05T02:43:27.317361Z",{"nct_id":87,"title":88,"phases":89,"status":90,"updated_at":91,"content_modified":92},"NCT05730465","Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor",[],"UNKNOWN","2026-08-03T02:58:35.674064Z","2026-05-05T02:43:28.973671Z",[],[95],{"state":96,"count":97,"slug":98},"California",6,"california"]